Skip to main content

Advertisement

SpringerLink
Log in

Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

Three years after the introduction of antiretroviral therapy (ART) in Tunisia (North Africa), we aimed to determine the prevalence of drug resistance mutations in Tunisian HIV-1-infected patients failing ART. Plasma samples of 80 patients were tested for genotypic resistance using two distinct line probe assays, LiPA HIV-1 reverse transcriptase RT and LiPA HIV-1 protease assay. Of the 80 patients, 82.5% showed resistance to at least one antiretroviral molecule. In the RT gene, resistance to nucleoside RT inhibitors (NRTIs) and non-nucleoside RT inhibitors (NNRTIs) were recognized in 66.25 and 37.5%, respectively, with M184V, T215Y and K103N being the codons most frequently involved. Resistance to protease inhibitors (PIs) was found in 46.25% of cases. Despite the presence of different mutations, the viral variants were still susceptible to other RTIs and PIs that are currently not available in Tunisia. Thus, alternative therapeutic options exist but are not yet accessible.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Wainberg MA, Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977–1983

    Article  PubMed  CAS  Google Scholar 

  2. Mellors JW, Munoz A et al (1997) Plasma viral load and CD4 + lymphocytes as prognostic markers of HIV-1 infection. Ann Int Med 126:946–954

    PubMed  CAS  Google Scholar 

  3. MacArthur RD, Chen L, Peng G et al (2004) Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons. HIV Clin Trials 5:361–370

    Article  PubMed  CAS  Google Scholar 

  4. Palella FJ, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV outpatient study investigators. N Engl J Med 338:853–860

    Article  PubMed  Google Scholar 

  5. Young B, Johnson S, Bahktiari M et al (1998) Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J Infect Dis 178:1497–1501

    Article  PubMed  CAS  Google Scholar 

  6. Valdez H, Connick E, Smith KY et al (2002) Limited immune restoration after 3 years’ suppression of HIV-1 replication in patients with moderately advanced disease. Aids 16:1859–1866

    Article  PubMed  CAS  Google Scholar 

  7. Tee KK, Kamarulzaman A, Ng KP (2006) Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. Med Microbiol Immunol 195:107–112

    Article  PubMed  CAS  Google Scholar 

  8. Rousseau MN, Vergne L, Montes B et al (2001) Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 26:36–43

    PubMed  CAS  Google Scholar 

  9. Pialoux G, Raffi F, Brun-Vezinet F et al (1998) A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 339:1269–1276

    Article  PubMed  CAS  Google Scholar 

  10. Napravnik S, Edwards D, Stewart P et al (2005) HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 40:34–40

    Article  PubMed  CAS  Google Scholar 

  11. Fatkenheuer G, Theisen A, Rockstroh J et al (1997) Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. Aids 11:F113–116

    Article  PubMed  CAS  Google Scholar 

  12. Katzenstein DA, Hammer SM, Hughes MD et al (1996) The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 335:1091–1098

    Article  PubMed  CAS  Google Scholar 

  13. Condra JH, Schleif WA, Blahy OM et al (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569–571

    Article  PubMed  CAS  Google Scholar 

  14. Descamps D, Flandre P, Calvez V et al (2000) Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team). JAMA 283:205–211

    Article  PubMed  CAS  Google Scholar 

  15. Ben Halima M, Pasquier C, Slim A et al (2001) First molecular characterization of HIV-1 Tunisian strains. J Acquir Immune Defic Syndr 28:94–96

    PubMed  CAS  Google Scholar 

  16. Direction des Soins de Santé de Base (DSSB). Ministère de la santé publique (2005) Rapport annuel.

  17. Obermeyer CM (2006) HIV in the Middle East. BMJ 333:851–854

    Article  PubMed  Google Scholar 

  18. Ben Mamou M, Slim A, Garbouj M et al (2006) Virological diagnosis and follow-up of HIV infection. State of the art and situation in Tunisia. Tunis Med 84:395–402

    PubMed  Google Scholar 

  19. Zouiten F, Ammari L, Goubantini A et al (2003) Effect of triple antiretroviral therapy on Tunisian AIDS profile: study of 139 cases. Tunis Med 81:956–962

    PubMed  Google Scholar 

  20. Stuyver L, Wyseur A, Rombout A et al (1997) Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 41:284–291

    PubMed  CAS  Google Scholar 

  21. Kuritzkes D (2002) Drug resistance. Navigating resistance pathways. AIDS Read 12:395–400, 407

    Google Scholar 

  22. Vandamme AM, Van Laethem K, De Clercq E (1999) Managing resistance to anti-HIV drugs: an important consideration for effective disease management. Drugs 57:337–361

    Article  PubMed  CAS  Google Scholar 

  23. Hirsch MS, Brun-Vezinet F, D’Aquila RT et al (2000) Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 283:2417–2426

    Article  PubMed  CAS  Google Scholar 

  24. Hirsch MS, Richman DD (2000) The role of genotypic resistance testing in selecting therapy for HIV. JAMA 284:1649–1650

    Article  PubMed  Google Scholar 

  25. Cerqueira DM, Amorim RM, Silva RR et al (2004) Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. Mem Inst Oswaldo Cruz 99:877–882

    Article  PubMed  CAS  Google Scholar 

  26. Costagliola D, Descamps D, Assoumou L, et al. (2007) Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr 46:12–18

    PubMed  CAS  Google Scholar 

  27. Gupta RK, Pillay D (2007) HIV resistance and the developing world. Int J Antimicrob Agents 29:510–517

    Article  PubMed  CAS  Google Scholar 

  28. Nkengasong JN, Adje-Toure C, Weidle PJ (2004) HIV antiretroviral drug resistance in Africa. AIDS Rev 6:4–12

    PubMed  Google Scholar 

  29. Chesney MA, Ickovics J, Hecht FM et al. (1999) Adherence: a necessity for successful HIV combination therapy. Aids 13(A):S271–278

    PubMed  Google Scholar 

  30. Bangsberg DR, Charlebois ED, Grant RM et al (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. Aids 17:1925–1932

    Article  PubMed  Google Scholar 

  31. Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15:247–277

    Article  PubMed  CAS  Google Scholar 

  32. Shah B, Walshe L, Saple DG et al (2007) Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis 44:1235–1244

    Article  PubMed  Google Scholar 

  33. Moyle GJ (1997) Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 40:765–777

    Article  PubMed  CAS  Google Scholar 

  34. D’Aquila RT, Schapiro JM, Brun-Vezinet F et al (2002) Drug Resistance Mutations in HIV-1. Top HIV Med 10:21–25

    PubMed  Google Scholar 

  35. Condra JH, Holder DJ, Schleif WA et al (1996) Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 70:8270–8276

    PubMed  CAS  Google Scholar 

  36. Servais J, Lambert C, Fontaine E et al (2001) Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy. J Clin Microbiol 39:454–459

    Article  PubMed  CAS  Google Scholar 

  37. Boden D, Hurley A, Zhang L et al (1999) HIV-1 drug resistance in newly infected individuals. Jama 282:1135–1141

    Article  PubMed  CAS  Google Scholar 

  38. Stone DR, Corcoran C, Wurcel A et al (2002) Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. Clin Infect Dis 35:883–886

    Article  PubMed  Google Scholar 

  39. Akinsete O, Hirigoyen D, Cartwright C et al (2004) K103 N mutation in antiretroviral therapy-naive African patients infected with HIV type 1. Clin Infect Dis 39:575–578

    Article  PubMed  CAS  Google Scholar 

  40. Soriano V (1999) Prevalence of drug resistance mutations in Spain among both naive and pretreated patients. Antivir Ther 4(3):57–63

    PubMed  Google Scholar 

  41. Ribeiro RM, Bonhoeffer S, Nowak MA (1998) The frequency of resistant mutant virus before antiviral therapy. Aids 12:461–465

    Article  PubMed  CAS  Google Scholar 

  42. Kozal MJ, Amico KR, Chiarella J et al (2004) Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care. Aids 18:2185–2189

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was performed at the National HIV Reference Laboratory, Charles Nicolle Hospital, Tunis, Tunisia. The expert assistance of the laboratory staff is gratefully acknowledged. The Department of Public Health (Direction des Soins de Santé de Base) and the Department of Higher education financed this work.

Author information

Authors and Affiliations

  1. Laboratoire de Microbiologie, Hôpital Charles Nicolle, Tunis, Tunisia

    A. Jlizi, A. Slim, M. Ben Mamou & S. Ben Rejeb

  2. Laboratoire de Génétique, Immunologie et pathologies Humaines, Faculté des Sciences de Tunis, Université Tunis El-Manar, Campus universitaire El Manar II, 2092, Tunis, Tunisia

    A. Jlizi, A. Ben Ammar El Gaaied & F. Tebourski

  3. Service de Pathologie Infectieuse, Hôpital La Rabta, Tunis, Tunisia

    T. Ben Chaabane

  4. Service de Pathologie Infectieuse, Hôpital Farhat Hached, Sousse, Tunisia

    A. Letaief-Omezzine

  5. Service de Pathologie Infectieuse, Hôpital Fattouma Bourguiba, Monastir, Tunisia

    M. Chakroun

  6. Direction des Soins de Santé de Base, Ministère de la Santé Publique, Tunis, Tunisia

    M. Garbouj

Authors
  1. A. Jlizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Ben Ammar El Gaaied
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Slim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Tebourski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Ben Mamou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Ben Chaabane
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Letaief-Omezzine
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Chakroun
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Garbouj
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. Ben Rejeb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Jlizi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jlizi, A., Ben Ammar El Gaaied, A., Slim, A. et al. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy. Arch Virol 153, 1103–1108 (2008). https://doi.org/10.1007/s00705-008-0104-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-008-0104-z

Keywords

Search

Navigation